

# Isaac B Hilton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3863131/publications.pdf>

Version: 2024-02-01

16  
papers

3,085  
citations

623734

14  
h-index

888059

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

4779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. <i>Nature Biotechnology</i> , 2015, 33, 510-517.	17.5	1,487
2	CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. <i>Nature Biotechnology</i> , 2017, 35, 561-568.	17.5	362
3	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. <i>Nature Methods</i> , 2016, 13, 127-137.	19.0	341
4	Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. <i>Nucleic Acids Research</i> , 2014, 42, e147-e147.	14.5	301
5	Engineering the next generation of cell-based therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 655-675.	46.4	93
6	Enabling functional genomics with genome engineering. <i>Genome Research</i> , 2015, 25, 1442-1455.	5.5	89
7	mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis. <i>Cancer Research</i> , 2013, 73, 2235-2246.	0.9	65
8	Distinct p53, p53:LANA, and LANA Complexes in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas. <i>Journal of Virology</i> , 2010, 84, 3898-3908.	3.4	62
9	Transgenic mice for in vivo epigenome editing with CRISPR-based systems. <i>Nature Methods</i> , 2021, 18, 965-974.	19.0	56
10	Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome- and transcriptome-wide off-target effects. <i>Science Advances</i> , 2020, 6, eaba1773.	10.3	55
11	CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility. <i>Trends in Biotechnology</i> , 2021, 39, 678-691.	9.3	47
12	Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase. <i>Nature Communications</i> , 2021, 12, 896.	12.8	39
13	The Open Chromatin Landscape of Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Virology</i> , 2013, 87, 11831-11842.	3.4	38
14	Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 688132.	4.8	21
15	Quantitative Analysis of the Bidirectional Viral G-Protein-Coupled Receptor and Lytic Latency-Associated Nuclear Antigen Promoter of Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Virology</i> , 2012, 86, 9683-9695.	3.4	9
16	Chemical control for CRISPR editing. <i>Nature Chemical Biology</i> , 2017, 13, 2-3.	8.0	3